Latest It Distribution News

Fletcher Building has agreed to sell its Construction Division to global giant VINCI Construction for an initial $315.6 million, with potential to rise to $334.1 million. The move marks a strategic pivot towards focused building products manufacturing.

Arena REIT has announced an ordinary quarterly dividend of AUD 0.048125 per security, payable on 5 February 2026, alongside a Dividend Reinvestment Plan priced at AUD 3.50330, offering investors a 1.5% discount.

Orthocell Limited has reported a record $3.2 million revenue for the December 2025 quarter, marking its seventh consecutive quarter of growth, fuelled by expanding sales of its nerve repair product Remplir in the US and other international markets.

Metcash Limited has updated its dividend distribution details, confirming a fully franked ordinary dividend of 8.5 cents per share and setting the Dividend Reinvestment Plan price at AUD 3.30 per share for the upcoming payment.

Tetratherix has inked a global exclusive distribution agreement with healthcare giant Henry Schein, paving the way for its first bone regeneration product, Tegenix, to enter major markets in 2026. Concurrently, the company has begun building an advanced manufacturing facility to meet expected global demand.

A few stocks did the heavy lifting this week, with one biotech exploding higher and a gas name collapsing on the other side of the ledger. Big moves came from capital raises, regulator decisions, and drill results that investors treated as near-term value, not distant promises.

Banco Santander has launched a A$450 million tranche of floating rate senior notes due in 2031, targeting exclusively professional and eligible counterparties under MiFID II regulations. The notes offer a quarterly interest rate tied to the 3-month BBSW plus a margin of 0.97%.

Cyprium Metals has secured $80 million in funding and advanced key infrastructure works to restart copper production at its Nifty Copper Complex, targeting first cathode output by mid-2026.

Wellnex Life reports a $2.4 million EBITDA improvement in H1 FY26 and reaches breakeven by Q2, supported by strong Pain Away sales and expanded distribution.

Orthocell has increased its investment in Marine Biomedical to 11.7%, securing exclusive distribution rights to the innovative PearlBone™ technology as it nears FDA approval.

Osteopore Limited has secured an exclusive multi-year distribution agreement with Majeton to commercialise its dental and maxillofacial products in China, Hong Kong, and Macau, marking a major step in its Asia-Pacific expansion.

Critical Metals Corp reports robust 2025 drilling results at the Tanbreez Rare Earths Project, confirming consistent high-grade rare earth mineralisation with strategic metals. These findings underpin plans for resource growth and mine development.